Incidence of Newly Registered Blindness From Age-Related Macular Degeneration in Australia Over a 21-Year Period: 1996-2016.
Journal
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
ISSN: 2162-0989
Titre abrégé: Asia Pac J Ophthalmol (Phila)
Pays: China
ID NLM: 101583622
Informations de publication
Date de publication:
16 Sep 2021
16 Sep 2021
Historique:
pubmed:
18
9
2021
medline:
26
11
2021
entrez:
17
9
2021
Statut:
epublish
Résumé
Report the age-standardized annual incidence of blindness registration due to age-related macular degeneration (AMD) in Australia in patients aged 50 years and older. Frequencies of photodynamic therapy (PDT) and intravitreal therapy (IVT) were examined. Retrospective observational study. Registry of the Association for the Blind of Western Australia with best-corrected visual acuity worse than 20/200 in the better-seeing eye. Registering as blind aged 50 years or over. Annual age-standardized incidence of blindness over 3 time periods: 1996-2001 (pre-PDT), 2002-2007 (PDT era) and 2008-2016 (IVT era). The rates of PDT and IVT usage were assessed. Age-standardized annual incidence of blindness rose during the PDT era, reaching 72.5 cases per 100,000 person-years in 2004. The incidence declined from 2007 onwards, reaching 8.2 cases per 100,000 person-years in 2016 (IVT era). The age at AMD blindness registration increased from 82.7 to 84.9 and 83.7 to 86.0 years from the PDT era to the IVT era in both male and females (P < 0.001) respectively. Over the same time period, PDT usage increased in 2002 and declined in 2006, whereas IVT usage increased from 2009 by 3745 per year. The increase in new blindness registrations due to AMD coincided with public funding of verteporfin for PDT, whereas the subsequent decline occurred when bevacizumab was used off-label and ranibizumab and aflibercept were publicly funded. An understanding of the effect of retinal therapy on public health measures may inform improvements in the allocation of limited resources.
Identifiants
pubmed: 34534144
doi: 10.1097/APO.0000000000000415
pii: 01599573-900000000-99675
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
442-449Informations de copyright
Copyright © 2021 Asia-Pacific Academy of Ophthalmology. Published by Wolters Kluwer Health, Inc. on behalf of the Asia-Pacific Academy of Ophthalmology.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Buch H, Vinding T, La Cour M, et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults. Ophthalmology 2004; 111:53–61.
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844–851.
Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291:1900–1901.
Skaat A, Chetrit A, Belkin M. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012; 153:214–221.
Crewe J, Morgan WH, Morlet N, et al. Prevalence of blindness in Western Australia: a population study using capture and recapture techniques. Br J Ophthalmol 2012; 96:478–481.
Yong VK, Morgan WH, Cooper RL, et al. Trends in registered blindness and its causes over 19 years in Western Australia. Ophthalmic Epidemiol 2006; 13:35–42.
Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 2012; 130:794–795.
Bloch S. Larsen, Munch I. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153:209–213.
Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds 2005e2010: is the incidence falling? Eye 2012; 26:933–936.
Keel S, Xie J, Foreman J, et al. Prevalence of age-related macular degeneration in australia the australian national eye health survey. JAMA Ophthalmol 2017; 135:1242–1249.
Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016; 3:34.
Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab or choroidal neovascularisation: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011; 129:709–717.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419–1431.
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432–1444.
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897–1908.
The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897–1908.
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537–2548.
Australian Government Services Australia. Medicare Statistics: Medicare Item Reports. Canberra: Last updated: 24 July 2020. Available at http://medicarestatistics.humanservices.gov.au/statistics/mbs_item.jsp Accessed September 27, 2020.
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329–1345.
Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119:198–207.
Blumenkranz MS, Bressler NM, Bressler SB, et al. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol 2002; 120:1307–1314.
Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 2020; 127:186–195.
Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 2018; 136:666–677.
Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology 2018; 125:1556–1567.
Fasler K, Fu DJ, Moraes G, et al. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration. Br J Ophthalmol 2020; 104:684–690.
Carneiro A, Andrade JP. Nutritional and lifestyle interventions for age-related macular degeneration: a review. Oxid Med Cell Longev 2017; 2017:6469138.
The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + Zeaxanthin and Omega-3 fatty acids for age-related macular degeneration: the age-related eye disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309:2005–2015.
Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96:752–756.
Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119:571–580.
Endophthalmitis Study Group. European Society of Cataract and Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007; 33:978–988.
Jørstad ØK, Steffensen LA, Eriksen K, et al. Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway. Acta Ophthalmol 2020; 98:774–779.
Johnston RL, Lee AY, Buckle M, et al. UK age-related macular degeneration electronic medical record system (AMD EMR) users group Report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology 2016; 123:2386–2392.